Health News

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that it will host an industry session at the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) on March 22, 2026, from 2:30pm - 4pm CET in Madrid, Spain. The session, titled “Advances in TA-TMA Treatment: Evaluating the Role of a Novel Targeted Therapy,” will be co-chaired by Rafael Duarte, MD, PhD, Hospital Universitario Puerta de Hierro Majadahonda, and Mohamad Mohty, MD, PhD, Hôp...

SEATTLE & COLUMBUS, Ohio--(BUSINESS WIRE)--Curi Bio and Battelle Announce Strategic Partnership to Accelerate the Adoption of NAMs in Neuromuscular Pharmacology...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that it has received notice of an unsolicited mini-tender offer by Tutanota LLC (“Tutanota”) to purchase up to 1 million shares of Pfizer common stock at a price of $32.00 per share in cash. The offer price of $32.00 per share is conditioned on, among other things, the closing price per share of Pfizer common stock exceeding $32.00 per share on the last trading day before the offer expires. This means that unless this condition...

RESTON, Va.--(BUSINESS WIRE)--TekSynap is proud to announce it has been awarded a position on the General Services Administration’s Alliant 3 Governmentwide Acquisition Contract, a Best-in-Class, pre-competed, multiple-award contract vehicle designed to help federal agencies acquire complex enterprise IT services and solutions with speed, consistency, and value. GSA announced the phase 1 awards on February 20, 2026, and the vehicle went live for ordering on March 10, 2026. Alliant 3 expands ear...

ORLANDO, Fla.--(BUSINESS WIRE)--Imaginostics, Inc. today announced that it has received a Letter of Support from Siemens Healthineers in connection with ongoing exploratory discussions regarding potential collaboration in quantitative MRI and imaging biomarkers. As part of these discussions, Imaginostics and Siemens Healthineers intend to continue dialogue concerning potential technical and commercial pathways for Imaginostics’ envisioned ImagiView™ and ImagiSight™ offerings and their potential...

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS) a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant during March 2026 of an aggregate of 85,516 restricted stock units (RSUs) and 8,635 stock options of the company’s common stock to 10 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company’s board of directors under the Evolus’ 2023 Inducemen...

PROVO, Utah--(BUSINESS WIRE)--Nu Skin Enterprises, Inc. (NYSE: NUS) today announced the appointment of Chelsea Lantz as interim Chief Financial Officer, effective immediately. The appointment of Lantz comes after James Thomas stepped down as CFO to pursue an outside opportunity. “On behalf of our board, management and the entire Nu Skin team, we thank James for his leadership and significant contributions over 16 years at Nu Skin and wish him and his family well in their future pursuits,” said...

VANCOUVER, British Columbia & TORONTO--(BUSINESS WIRE)--WELL Health Technologies Corp. (TSX: WELL) (the “Company” or “WELL”), a digital healthcare company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, today expressed its strong support for the Ontario government’s announcement of a new provincewide Primary Care Medical Record system, and confirmed its intent to actively participate in the forthcoming pro...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), today announced that the Pharmaceutical Administration Bureau (ISAF) of the Macau Special Administrative Region of the People’s Republic of China has granted regulatory approval for ANKTIVA® (nogapendekin alfa inbakicept-pmln). The approval establishes ANKTIVA’s initial presence in Asia and reflects the Company’s strategy to expand global access through reliance-based regulatory pathways. In Macau, ANKTIVA is approved in co...